As of 2025-04-29, the Relative Valuation of Recursion Pharmaceuticals Inc (RXRX) is (16.84) USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.84 USD, the upside of Recursion Pharmaceuticals Inc based on Relative Valuation is -388.4%.
The range of the Relative Valuation is (15.39) - (24.11) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 23.9x | 15.1x |
| Forward P/E multiples | 12.5x - 20.9x | 14.1x |
| Fair Price | (15.39) - (24.11) | (16.84) |
| Upside | -363.5% - -512.8% | -388.4% |
| Date | P/E |
| 2025-04-28 | -5.06 |
| 2025-04-25 | -4.97 |
| 2025-04-24 | -4.99 |
| 2025-04-23 | -4.84 |
| 2025-04-22 | -4.88 |
| 2025-04-21 | -4.69 |
| 2025-04-17 | -4.77 |
| 2025-04-16 | -4.61 |
| 2025-04-15 | -4.89 |
| 2025-04-14 | -4.78 |
| 2025-04-11 | -4.99 |
| 2025-04-10 | -3.91 |
| 2025-04-09 | -4.03 |
| 2025-04-08 | -3.44 |
| 2025-04-07 | -3.64 |
| 2025-04-04 | -3.68 |
| 2025-04-03 | -4.17 |
| 2025-04-02 | -4.59 |
| 2025-04-01 | -4.42 |
| 2025-03-31 | -4.59 |
| 2025-03-28 | -5.04 |
| 2025-03-27 | -5.18 |
| 2025-03-26 | -5.35 |
| 2025-03-25 | -5.66 |
| 2025-03-24 | -5.89 |
| 2025-03-21 | -5.79 |
| 2025-03-20 | -5.62 |
| 2025-03-19 | -5.70 |
| 2025-03-18 | -5.54 |
| 2025-03-17 | -5.93 |
| 2025-03-14 | -5.51 |
| 2025-03-13 | -5.15 |
| 2025-03-12 | -5.35 |
| 2025-03-11 | -5.25 |
| 2025-03-10 | -5.31 |
| 2025-03-07 | -5.71 |
| 2025-03-06 | -5.41 |
| 2025-03-05 | -5.70 |
| 2025-03-04 | -5.61 |
| 2025-03-03 | -5.71 |
| 2025-02-28 | -6.51 |
| 2025-02-27 | -6.65 |
| 2025-02-26 | -7.23 |
| 2025-02-25 | -7.06 |
| 2025-02-24 | -7.80 |
| 2025-02-21 | -8.05 |
| 2025-02-20 | -8.97 |
| 2025-02-19 | -9.42 |
| 2025-02-18 | -9.22 |
| 2025-02-14 | -9.13 |